Ifirmacombi (Hydrochlorothiazide, Irbesartan)

Ifirmacombi is indicated for conditions within the hypertension therapeutic pathway.

• Hypertension: lowers systolic and diastolic blood pressure in adults.
• Resistant hypertension: provides additional blood pressure control when monotherapy is insufficient.
• Hypertensive patients with fluid retention: combines diuretic effect with ARB to reduce volume overload.

• Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing angiotensin‑II‑induced vasoconstriction and aldosterone secretion, which reduces peripheral resistance. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, increasing urinary excretion of sodium and water, thereby decreasing plasma volume. These mechanisms act simultaneously to improve vascular tone and reduce cardiac preload, offering a synergistic approach to blood pressure management.

Adverse reactions reported with the combination of irbesartan and hydrochlorothiazide cover a range of frequencies.

Common Side Effects

• Dizziness: light‑headed sensation, especially after standing.
• Headache: mild to moderate intensity.
• Fatigue: general tiredness.
• Increased urination: due to diuretic effect.
• Electrolyte imbalance: low potassium or sodium levels.
• Cough: occasional dry cough.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or airway.
• Severe hypotension: markedly low blood pressure.
• Acute kidney injury: sudden decline in renal function.
• Hyperkalemia: dangerously high potassium levels.
• Liver dysfunction: elevated liver enzymes or hepatitis.
• Blood dyscrasias: neutropenia or agranulocytosis.

When prescribing Ifirmacombi, clinicians should consider several precautionary measures to ensure safe use.

• Renal function: assess baseline kidney function and monitor periodically.
• Electrolytes: check serum potassium and sodium before initiation and during therapy.
• Volume status: evaluate for dehydration or excessive fluid loss.
• Concomitant drugs: avoid use with other potassium‑sparing agents without monitoring.
• Pregnancy: contraindicated in the second and third trimesters; assess risk‑benefit if used early.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Ifirmacombi may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Potassium supplements or potassium‑sparing diuretics: risk of hyperkalemia.
• NSAIDs (e.g., ibuprofen, naproxen): may reduce antihypertensive effect and impair renal function.
• Lithium: increased lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or other ARBs: additive risk of renal impairment and hyperkalemia.
• Antidiabetic agents (insulin, sulfonylureas): may enhance hypoglycemic effect.
• Antihypertensive agents (beta‑blockers, calcium channel blockers): may cause excessive blood pressure lowering.